Activin A, corticotropin-releasing factor and prostaglandin F2 alpha increase immunoreactive oxytocin release from cultured human placental cells.
The aim of the present study was to investigate the presence of the immunoreactive oxytocin in human placental extracts and putative factors regulating the release of immunoreactive oxytocin from cultured human placental cells. Fresh placental tissue was collected from pregnant women at term and dissected of membranes (n = 5). Presence of immunoreactive oxytocin in trophoblast tissue was evaluated by a specific radio-immunoassay after acidic extraction and high-pressure liquid chromatography. In a second set of experiments, primary cultures of placental cells were performed and, 48-72 h after dissociation, the effect of arginine vasopressin, corticotropin-releasing factor, neuropeptide Y, activin A, inhibin A, noradrenaline or prostaglandins on immunoreactive oxytocin level in culture medium was investigated. The presence of immunoreactive oxytocin was shown in the acidic extract of trophoblast at term, and in the culture medium of human placental cells, and it was identical to the native peptide. The addition of corticotropin-releasing factor or arginine vasopressin, but not of neuropeptide Y, increased the release of immunoreactive oxytocin three- to fourfold from placental cells, with a dose-dependent effect (P < 0.01). A significantly increased release of immunoreactive oxytocin was shown in presence of noradrenaline (P < 0.01), which was reversed by prazosin, an antagonist of alpha-adrenergic receptors. Recombinant human activin A (P < 0.01), but not inhibin A, stimulated the release of immunoreactive oxytocin three- to fourfold from placental cells. Prostaglandin F2 alpha was a potent secretagogue of immunoreactive oxytocin, whereas a partial or no effect was observed when prostaglandin E2 or prostaglandin I2 was added. Thus, the present findings showed that human placenta contains immunoreactive oxytocin, and that its release from cultured placental cells is regulated by neurohormones, growth factors or prostaglandins.
Florio
P
P
Department of Gynecology and Obstetric, Universities of Pisa, Italy.
Lombardo
M
M
Gallo
R
R
Di Carlo
C
C
Sutton
S
S
Genazzani
A R
AR
Petraglia
F
F
D028341:Activins; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D001127:Arginine Vasopressin / Q000494:pharmacology; D002478:Cells, Cultured; D002851:Chromatography, High Pressure Liquid; D003346:Corticotropin-Releasing Hormone / Q000494:pharmacology*; D003470:Culture Media; D015237:Dinoprost / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007265:Inhibins / Q000494:pharmacology*; D009638:Norepinephrine / Q000494:pharmacology; D010121:Oxytocin / Q000378:metabolism*; D010920:Placenta / Q000187:drug effects* / Q000378:metabolism*; D011224:Prazosin / Q000494:pharmacology; D011247:Pregnancy; D011994:Recombinant Proteins / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D003470:Culture Media; D011994:Recombinant Proteins; D028341:Activins; D001127:Arginine Vasopressin; D010121:Oxytocin; D007265:Inhibins; D003346:Corticotropin-Releasing Hormone; D015237:Dinoprost; D009638:Norepinephrine; D011224:Prazosin